3Jadwiga A Wedzicha,Terence AR Seemungal.COPD exacerbations: defining their cause and prevention[J]. The Lancet . 2007 (9589)
4Beuscher N,Kietzmann M,Bien E,Champeroux P.Interference of myrtol standardized with inflammatory and allergic mediators. Arzneimittel Forschung Drug Research . 1998
3Matzke H. Experienceswith Gelomyrtol in the treatment of bronchitis[J].MunchMedWochenschr, 1961, 29 (103) : 1881- 1882.
4Kurz JF. Secretolysis through gelomyrtol [J].ZAllgemeinmed, 1970, 46 (32): 1623-1627.
5Matthys H, de Mey C, Carls C, et al, Efficacy and tolerability ofmyrtol standardized in acute bronchitis [J]. Arzneimittelforschung, 2000, 50 (8):700-711.
6UlmerWT, SchottD. Chronic obstructive bronchitis. Effect of Gelomyrtol forte in a p lacebocontrolled double2blind study [J].Fortschr Med, 1991, 109 (27): 547-550.
7Sengespeik HC, Zimmermann T, Peike C, et al. Myrtol standardized in the treatment of acute and chronic respiratory infections in children [J]. Arzneimittelforschung, 1998, 48 (10) : 990-994.
8Meister R, Wittig T, BeuscherN, et al. Efficacy and tolerability ofmyrtol standardized in longterm treatment of chronic bronchitis. A double blind, placebocontrolled study. Study Group Investigators[J]. Arzneimittelforschung, 1999, 49 ( 4 ): 351-358.
9Beuscher N, Kietzmann M, Bien E, et al. Interference of Myrtol Standardized with Inflammatory and Allergic Mediators [J].Arzneimittelforsehung, 1998, 48 (10): 985-989.
10Behrbohm H, Kasehke O, Sydow K. The influence of a secre tolytic drug on mucociliary clearance of the maxillary sinus[J].J Rhinol, 1997, 4 (1): 29 -33.
